Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.66 |
| ▸ | TUBB | P07437 | 1/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.66 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.66 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.66 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.66 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652355 | 0.84 | TUBB4A (0.73) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL653473 | 0.83 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL650056 | 0.83 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL650441 | 0.80 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL653340 | 0.79 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL653946 | 0.79 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL651693 | 0.79 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12904686 | 0.79 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL652514 | 0.79 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL650403 | 0.78 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534675-B1 | FLUORO AND SULPHONYLAMINO CONTAINING 3,6-DISUBSTITUTED AZABICYCLO¬3.1.0 HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2009-02-25 | — | — | EP | claimed |
| US-7288562-B2 | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-30 | — | — | US | claimed |
| US-20060004083-A1 | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-01-05 | — | — | US | claimed |
| EP-1534675-A1 | FLUORO AND SULPHONYLAMINO CONTAINING 3,6-DISUBSTITUTED AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-01 | — | — | EP | claimed |
| WO-2004018422-A1 | FLUORO AND SULPHONYLAMINO CONTAINING 3,6-DISUBSTITUTED AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-03-04 | — | — | WO | claimed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-3042645-B2 | Dental composites with improved storage stability | IVOCLAR VIVADENT AG (LI) | 2025-03-12 | — | — | EP | disclosed |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-11-12 | — | — | US | disclosed |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-08-13 | — | — | US | disclosed |
| EP-0352083-B1 | Alkenyltetrazole derivatives, their preparation and use | SHIONOGI & CO (JP) | 1993-11-24 | — | — | EP | disclosed |
| EP-0255728-B1 | PHENOXYACETIC ACID COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4916231-A | THROMBOXANE A2 RECPTOR ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0352083-A2 | Alkenyltetrazole derivatives, their preparation and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1990-01-24 | — | — | EP | disclosed |
| US-4866196-A | ANTICOAGULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
| EP-0255728-A2 | Phenoxyacetic acid compounds, their preparation, pharmaceutical composition and use | TANABE SEIYAKU CO., LTD. (JP) | 1988-02-10 | — | — | EP | disclosed |
| US-4237130-A | DIURETICS, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4167567-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | TUBB4A 1358/4885TUBB 1811/4885TUBA3C 2765/4885 |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | TUBB4A 1358/4885TUBB 1811/4885TUBA3C 2765/4885 |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | TUBB4A 1358/4885TUBB 1811/4885TUBA3C 2765/4885 |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | TUBB4A 1358/4885TUBB 1811/4885TUBA3C 2765/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | TUBB4A 1420/4885TUBB 1896/4885TUBA3C 2826/4885 |
| US-20060004083-A1 | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, ADRB3 | TUBB4A 3928/4885TUBB 2905/4885TUBA3C 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.